Sunitinib Malate Global Strategic Business Report 2024-2030: Emerging Clinical Trials for Combination Therapies Propels Competitiveness
11 nov. 2024 11h04 HE
|
Research and Markets
Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "Sunitinib Malate - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Sunitinib Malate...
Liposomal Doxorubicin Market Report 2024-2032: Innovative Liposomal Formulations Pave the Way for Safer and More Effective Cancer Treatments
07 nov. 2024 08h04 HE
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global liposomal...
$1.89 Bn Liposomal Doxorubicin Markets, 2024-2030: Focus on Doxil/Caelyx, Lipodox, and Myocet
30 sept. 2024 05h50 HE
|
Research and Markets
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By...
Thyroid Cancer Therapeutics Market Research Report 2024: Comprehensive Insights About 50+ Companies and 51+ Pipeline Drugs
24 sept. 2024 11h29 HE
|
Research and Markets
Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Thyroid Cancer - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest analytical report reveals a dynamic...
Doxorubicin Industry Research Report 2024-2030
23 sept. 2024 09h54 HE
|
Research and Markets
Dublin, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By...
Doxorubicin Global Strategic Research Report 2024: Market to Reach $1.7 Billion by 2030 from $1.1 Billion in 2023, Driven by Rise in Cancer Incidence and Innovations in Cancer Drug Delivery
05 avr. 2024 09h07 HE
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Doxorubicin Market to Reach $1.7...
Aflibercept (Eylea) Biosimilars Pipeline Review 2024: Patents are Due to Run out from 2023 to 2032
23 févr. 2024 07h32 HE
|
Research and Markets
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Aflibercept (Eylea) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Global Thyroid Cancer Drugs Market Report 2024: Highlights Trends in Targeted Therapies, Featuring Profiles of Mylan Pharmaceuticals, AstraZeneca, Exelixis, Pfizer, and Bristol-Myers Squibb
23 janv. 2024 15h28 HE
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Global Market 2024" report has been added to ResearchAndMarkets.com's offering. The global thyroid cancer drugs market...
Pemetrexed + Cisplatin Drug Insights and Market Forecasts 2019-2032: The Standard of Care Front Line Regimen for Malignant Pleural Mesothelioma
12 déc. 2023 04h58 HE
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
Global Thyroid Cancer Drugs Market to Reach $1.29 Billion by 2027: Targeted Therapies Transforming Thyroid Cancer Treatment
31 juil. 2023 05h33 HE
|
Research and Markets
Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Global Market Report 2023" has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive guide to...